Allergy Asthma Immunol Res:特应性皮炎、哮喘和过敏性鼻炎患者的生活质量和心理健康状况如何?

2022-04-11 AlexYang MedSci原创

近日,来自韩国天主教大学的研究人员调查了过敏性疾病患者与非过敏性对照组人群的心理健康状况和生活质量。相关研究结果发表在Allergy Asthma Immunol Res期刊上。

近日,来自韩国天主教大学的研究人员调查了过敏性疾病患者与非过敏性对照组人群的心理健康状况和生活质量。相关研究结果发表在Allergy Asthma Immunol Res期刊上。

本研究采用2016年至2018年韩国全国健康与营养调查的全国性、基于人口的横断面数据。研究使用倾向性匹配得分来平衡过敏性疾病组和相应对照组之间的年龄和性别分布。特应性皮炎(n = 446)和哮喘(n = 483)组与对照组按1:10的比例进行比较,过敏性鼻炎(n = 2357)组与对照组按1:2的比例进行比较。研究人员使用多重逻辑回归分析来评估基于过敏性疾病存在的心理健康状况和健康相关生活质量(HRQoL)的几率(ORs)。

结果显示,调整混杂因素后,哮喘组(OR,1.41,1.83和2.1)和过敏性鼻炎组(OR,1.35,1.48和1.83)与非过敏性对照组相比,严重心理压力、心理咨询和抑郁症诊断的OR显著增加。与对照组相比,哮喘组的活动能力出现严重问题的比率有更明显的增加。

图1 过敏性疾病患者心理健康状况及健康相关生活质量分析

因此,研究人员认为应努力管理特应性皮炎、哮喘和过敏性鼻炎患者心理问题,改善的他们的HRQoL。

 

原始出处:

Lee GN, Koo HYR, Han K, et al. Analysis of Quality of Life and Mental Health in Patients With Atopic Dermatitis, Asthma and Allergic Rhinitis Using a Nation-wide Database, KNHANES VII. Allergy Asthma Immunol Res. 2022 Mar;14.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]
    2022-12-25 skhzy
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]
    2022-04-12 DR.Fu SIR

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]
    2022-04-11 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]
    2022-04-10 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=2047468, encodeId=f116204e468b6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Oct 31 14:15:31 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1713051, encodeId=8b341e130516f, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 19 11:15:31 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977187, encodeId=9f9019e7187b7, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Sun Dec 25 02:15:31 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210480, encodeId=12191210480b2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 09:07:44 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210389, encodeId=c84d12103893d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 11 22:11:16 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329611, encodeId=fd3a1329611c3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511053, encodeId=d355151105328, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Sun Apr 10 12:15:31 CST 2022, time=2022-04-10, status=1, ipAttribution=)]

相关资讯

上海东方医院护士不幸去世,医院发布声明:深感痛心!

南院急诊部因疫情防控需要,正暂时关闭。

JACIP:Dupilumab单抗显示对特应性皮炎、哮喘、鼻窦炎并鼻息肉的快速反应

Dupilumab被批准用于治疗某些中到重度特应性皮炎(AD)、中到重度哮喘和慢性鼻-鼻窦炎并鼻息肉患者。本文评估了139名患者在接受dupilumab治疗中症状和临床相关结果有意义的变化。

Radiology:让我们通过3He MRI重新认识CT上发现的粘液栓!

通气异质性是哮喘的基础病理生理特征,可通过超极化氦3(3He)MRI观察到的通气障碍反映。

不敢用药,怀孕的哮喘患者怎么办?

30岁女性,目前怀孕13周。最近1个月哮喘反复发作,自己能听到夜间有喘鸣声,有时胸口闷,像有东西压住,需要坐起来用力呼吸,白天好转,能比较正常活动,有时咳嗽,干咳无痰,晚上多一些。

PAL:持续性哮喘患者在儿童早期即出现肺功能受损

女性、接受ICS治疗和频繁哮喘急性加重是儿童持续性哮喘的危险因素。

Lancet子刊:小气道疾病与哮喘结局显著相关,ATLANTIS前瞻性队列研究数据给出答案

为了更好的治疗哮喘患者,应评估小气道功能、大气道功能和生物标记物,作为哮喘表型的一部分,以更好地了解患者预后不良的风险。